Literature DB >> 1794362

Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.

H Hanberger1, L E Nilsson, M Nilsson, R Maller.   

Abstract

The in vitro post-antibiotic effect (PAE) of cefepime, cefotaxime, ceftazidime and imipenem on reference strains of Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens were evaluated by bioluminescence assay of bacterial ATP. In parallel with the PAE determination, initial killing and morphology studies were performed. Imipenem produced greater than 1 h PAE on all strains tested, cefepime and cefotaxime on four strains and ceftazidime only on one of the strains tested. The length of the PAE on different strains did not correlate in the same way to MIC. Imipenem induced greater than 1 h PAE at 1/4-2 MIC while the cephalosporins caused greater than 1 h PAE at 4-256 x MIC. A PAE exceeding 1.2h was seen concomitantly with spheroplasts but there was not necessarily strong (greater than or equal to 99%) initial killing at the same time. The PAE duration at greater than or equal to 99% initial killing varied between 2.0 h and 5.0 h. When the cephalosporins produced less than 1 h PAEs, this was seen concomitantly with production on filaments and weak initial killing. The bioluminescence method was not jeopardized by filament formation and no negative PAE was found in contrast to the viable count method. The study showed that neither a certain multiple of MIC, the presence of spheroplasts nor strong initial killing can predict the length of PAE for beta-lactam antibiotics on gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794362     DOI: 10.1007/BF02005446

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  The post-antibiotic effect defined by bacterial morphology.

Authors:  V Lorian; J Ernst; L Amaral
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

2.  The postantibiotic effect of imipenem.

Authors:  N Manek; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

3.  An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions.

Authors:  T Bergan; I B Carlsen; J E Fuglesang
Journal:  Infection       Date:  1980       Impact factor: 3.553

4.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  Effects of Escherichia coli spheroplast formation on assays of H2 and adenosine triphosphate based ampicillin susceptibility tests.

Authors:  E G Hörnsten; L E Nilsson; H Elwing; I Lundström
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Mar-Apr       Impact factor: 2.803

Review 6.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

7.  Ways to overcome cephalosporinase-mediated beta-lactam resistance in Enterobacter cloacae.

Authors:  R L Then; P Angehrn
Journal:  Chemioterapia       Date:  1985-02

8.  The in-vivo postantibiotic effect of imipenem and other new antimicrobials.

Authors:  S Gudmundsson; B Vogelman; W A Craig
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

9.  Selective growth of resistant variants during incubation of Enterobacteriaceae with four aminoglycosides.

Authors:  L Nilsson; L Sörén
Journal:  J Antimicrob Chemother       Date:  1986-09       Impact factor: 5.790

10.  Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions.

Authors:  T Bergan; I B Carlsen
Journal:  Infection       Date:  1980       Impact factor: 3.553

View more
  16 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Cell-Size Homeostasis and the Incremental Rule in a Bacterial Pathogen.

Authors:  Maxime Deforet; Dave van Ditmarsch; João B Xavier
Journal:  Biophys J       Date:  2015-08-04       Impact factor: 4.033

3.  Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilms.

Authors:  Tricia A Van Laar; Tsute Chen; Tao You; Kai P Leung
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

Review 4.  Antibiotic-induced release of endotoxin. A therapeutic paradox.

Authors:  J C Hurley
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

5.  Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods.

Authors:  F M MacKenzie; I M Gould; D G Chapman; D Jason
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Retain intermittent dosing of carbapenems.

Authors:  H Hanberger; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

7.  Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

Authors:  Wolfgang A Krueger; Jurgen Bulitta; Martina Kinzig-Schippers; Cornelia Landersdorfer; Ulrike Holzgrabe; Kurt G Naber; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 8.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

10.  Altered pharmacokinetics of ceftazidime in critically ill patients.

Authors:  C M Gómez; J J Cordingly; M G Palazzo
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.